Efficiency and Toxicity of Imatinib Mesylate Combined with Atorvastatin Calcium in the Treatment of Steroid-Refractory Chronic Graft-versus-Host Disease: A Single-Center, Prospective, Single-Arm, Open-Label Study
Acta Haematologica · 2024
DOI: 10.1159/000536174 ↗Kurz gefasst
Klinische Studie in der Zeitschrift Acta Haematologica, 2024. Verfasst von Ting Chen und 17 weiteren Autor:innen. Beteiligte Einrichtung: Medical Center of Hematology, Xinqiao Hospital of Army Medical University, State Key Laboratory of Trauma, Burns and Combined Injury, Chongqing, Chin…. Hauptthemen laut MEDLINE: Graft vs Host Disease, Imatinib Mesylate, Atorvastatin. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 48 Literaturangaben.
Abstract (Originalsprache)
Introduction
Steroid-refractory cGVHD (SR-cGVHD) presents new great challenges for treatment. We have reported that imatinib monotherapy was effective to SR-cGVHD, but the CR rate was not satisfactory and the benefit was not showed specific to some target organs, previously. Imatinib and statin drugs have been recognized to regulate T-cell function, statins also have been demonstrated endothelia protection, but whether this combination therapy was able to improve the efficacy remains unknown. Therefore, we designed this prospective, single-arm, open-label trial to investigate the efficacy of imatinib-based combination therapy in the treatment of SR-cGVHD for the first time.
Methods
Sixty SR-cGVHD patients were entered into this trial to investigate the combination of imatinib mesylate and atorvastatin calcium for the treatment of SR-cGVHD. The primary endpoint included the overall response rate (ORR) after 6 months of combined treatment. The secondary endpoints included an evaluation of survival, changes in T-cell subsets, and adverse events.
Results
At baseline, 45% (27/60) of patients had moderate cGVHD, and 55.0% (33/60) of patients had severe cGVHD. At the 6-month follow-up, a clinical response was achieved in 70.0% of patients, and a complete response (CR) was achieved in 26.7%. A total of 11.7% (7/60) of patients stopped immunosuppressive therapy at this point. After 6 months of treatment, the ORR rates of the liver, skin, eyes, and oral cavity were 80.6%, 78.1%, 61.5%, and 60.9%, respectively, with the liver also having the highest CR of 58.1%. The patients with moderate cGVHD had a better CR rate than those with severe cGVHD (55.6% vs. 3.0%, p < 0.0001). The overall survival in patients with ORR was improved (p = 0.0106). Lung involvement is an independent risk factor to affected ORR achievement (p = 0.021, HR = 0.335, 95% CI: 0.133–0.847), and the dosage of steroids was reduced in ORR patients. In clinical response patients, the ratio of CD8+ T cells (p = 0.0117) and Th17 cells (p = 0.0171) decreased, while the number of Treg cells (p = 0.0147) increased after 3 months. The most common adverse events were edema, nausea, and neutropenia, which were 13.3%, 11.7%, and 11.7%, respectively.
Conclusion
Combination treatment with imatinib mesylate and atorvastatin calcium was effective in treating SR-cGVHD and significantly decreased target organ injury, especially liver damage, indicating that T-cell regulatory function may play an important role in this process.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Medical Center of Hematology, Xinqiao Hospital of Army Medical University, State Key Laboratory of Trauma, Burns and Combined Injury, Chongqing, China.
- Department of Endocrinology, The General Hospital of Western Theater Command PLA, Sichuan, China.
Zitieren
APA
Chen, T., Li, J., Wei, X., Yao, H., Zhu, L., Liu, J., Liu, Y., Wang, P., Feng, Y., Gao, S., Liu, H., Wang, L., Zhao, L., Gao, L., Zhang, C., Gao, L., Zhang, X., & Kong, P. (2024). Efficiency and Toxicity of Imatinib Mesylate Combined with Atorvastatin Calcium in the Treatment of Steroid-Refractory Chronic Graft-versus-Host Disease: A Single-Center, Prospective, Single-Arm, Open-Label Study. Acta Haematologica. https://doi.org/10.1159/000536174
Vancouver
Chen T, Li J, Wei X, Yao H, Zhu L, Liu J, et al. Efficiency and Toxicity of Imatinib Mesylate Combined with Atorvastatin Calcium in the Treatment of Steroid-Refractory Chronic Graft-versus-Host Disease: A Single-Center, Prospective, Single-Arm, Open-Label Study. Acta Haematologica. 2024. doi:10.1159/000536174
BibTeX
@article{Chen2024,
author = {Chen, Ting and Li, JiaLi and Wei, Xiao and Yao, Han and Zhu, LiDan and Liu, Jia and Liu, YuQing and Wang, Ping and Feng, YiMei and Gao, ShiChun and Liu, HuanFeng and Wang, Lu and Zhao, Lu and Gao, Li and Zhang, Cheng and Gao, Lei and Zhang, Xi and Kong, PeiYan},
title = {Efficiency and Toxicity of Imatinib Mesylate Combined with Atorvastatin Calcium in the Treatment of Steroid-Refractory Chronic Graft-versus-Host Disease: A Single-Center, Prospective, Single-Arm, Open-Label Study},
journal = {Acta Haematologica},
year = {2024},
doi = {10.1159/000536174}
}
EUVIMED